Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | PRKDC | P78527 | 2/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | KMO | O15229 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10473981 | 0.83 | MAPT (0.56) | MAPTLMNAPRKDCAKR1C3KMO | |
| SCHEMBL6972013 | 0.81 | MAPT (0.55) | MAPTLMNAPRKDCAKR1C3KMO | |
| SCHEMBL19924287 | 0.81 | MAPT (0.52) | MAPTLMNAPRKDCGPR119AKR1C3 | |
| SCHEMBL15579306 | 0.81 | MLYCD (0.57) | MAPTAKR1C3SMN1; SMN2ALDH1A1HRH3 | |
| SCHEMBL16933596 | 0.81 | LMNA (0.47) | MAPTLMNAPRKDCGPR119SMN1; SMN2 | |
| SCHEMBL15578207 | 0.80 | HRH3 (0.62) | SMN1; SMN2ALDH1A1NPC1MAPK1RAB9A | |
| SCHEMBL26472636 | 0.80 | KMT2A (0.55) | MAPTLMNASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL15682635 | 0.79 | MAPT (0.52) | MAPTLMNAPRKDCAKR1C3KMO | |
| SCHEMBL4573348 | 0.78 | ALDH1A1 (0.54) | LMNAALDH1A1 | |
| SCHEMBL8431738 | 0.78 | SLC13A5 (0.52) | MAPTLMNAPRKDCAKR1C3KMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2025-01-23 | — | — | US | disclosed |
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2024-08-13 | — | — | US | disclosed |
| EP-4098654-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2022-12-07 | — | — | EP | disclosed |
| CN-114533729-A | Glucosylceramide synthase inhibitors | 建新公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20220073508-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2022-03-10 | — | — | US | disclosed |
| EP-2895484-B1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORP (US) | 2022-02-23 | — | — | EP | disclosed |
| CN-108864076-B | Glucosylceramide synthase inhibitors | 建新公司 | 2022-02-11 | — | — | CN | disclosed |
| US-11008316-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2021-05-18 | — | — | US | disclosed |
| US-20180065957-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2018-03-08 | — | — | US | disclosed |
| US-20150210681-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2015-07-30 | — | — | US | disclosed |
| EP-2895484-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2015-07-22 | — | — | EP | disclosed |
| WO-2014043068-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2014-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210681-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | MAPT 4277/4885LMNA 2630/4885PRKDC 3795/4885 |
| US-20180065957-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | MAPT 4277/4885LMNA 2630/4885PRKDC 3795/4885 |
| US-11008316-B2 | Glucosylceramide synthase inhibitors | GBA1, GBA2, GAA | MAPT 4300/4885LMNA 2203/4885PRKDC 3794/4885 |
| US-12060349-B2 | Glucosylceramide synthase inhibitors | GBA1, GBA2, GALC | MAPT 3852/4885LMNA 2655/4885PRKDC 3523/4885 |
| US-20250026749-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | MAPT 4277/4885LMNA 2630/4885PRKDC 3795/4885 |
| US-20220073508-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | MAPT 4277/4885LMNA 2630/4885PRKDC 3795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.